宁红欣改善肿瘤患者化疗后贫血的临床研究  

A clinical study of Ninghongxin in the treatment of chemotherapy-induced anemia in patients with cancer

作　　者：朱江[1] 侯梅[1] 勾红峰[1] 李璐[1] 邱萌[1] 

机构地区：[1]四川大学华西医院肿瘤中心化疗科,四川成都610041

出　　处：《华西药学杂志》2003年第4期310-311,共2页West China Journal of Pharmaceutical Sciences

摘　　要：目的　了解宁红欣能否改善化疗患者相关性贫血并提高其生活质量。方法　 2 8例患者随机分为研究组和对照组 ,所得的计量资料采用t检查。结果　治疗 4周后 ,研究组血色素平均值升高 2 6 8g·ml-1,对照组下降 18 2g·ml-1;研究组红细胞比容平均值升高 7 7%,对照组下降 6 %;研究组QOL评分平均上升 2 3分 ,对照组下降 0 7分。各组间差异均有统计学意义(P <0 0 0 1或P <0 0 5 )。结论　宁红欣能显著改善患者化疗后的相关性贫血 ;并可使其生活质量有所提高。OBJECTIVE To study the efficiency of recombinative human erythropoietin (rhEPO) in the treatment of chemotherapy-induced anemia.METHODS 28 chosen cases were randomized into test group and control group.We used t-test to examin the obtained measurement data.RESULTS The average haemoglobin level with rhEPO treatment had increased 26.8 g·ml -1in test group after 4 weeks and decreased 18.2 g·ml -1 in control group(P<0.001);The average hematocrit(Hct) level of test group had increased 7.7% after 4 weeks while decreased 6% in control group(P<0.001).The average quality of life (QOL) score of test group had increased 2.3 versus 0.7 down of control group after 4 weeks (P<0.05). CONCLUSION rhEPO in the treatment of chemotherapy-induced anemia is significantly effective.It also improves QOL in patients received chemotherapy.

关 键 词：肿瘤 化学治疗 贫血 宁红欣 促红细胞生成素 

分 类 号：R973.3[医药卫生—药品]